TrialNature medicine2018

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.

Andrew Tutt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.